Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Central Asia

Central Asia

The revenue in the Other Vaccines market in Central Asia is projected to reach US$55.97m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 11.59%, resulting in a market volume of US$96.86m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$24,730.00m in 2024.
Central Asian countries are experiencing a growing demand for other vaccines, driven by increased awareness of the importance of immunization and the expansion of healthcare systems.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Central Asia has been experiencing significant growth in recent years, driven by a variety of factors including customer preferences, local special circumstances, and underlying macroeconomic factors.

Customer preferences: Customers in Central Asia have shown a growing interest in preventative healthcare, leading to an increased demand for vaccines. Additionally, with the rise of medical tourism in the region, more individuals are seeking out vaccines as a precautionary measure before traveling to other countries.

Trends in the market: Kazakhstan has emerged as a key player in the Other Vaccines market in Central Asia, with a growing number of vaccine manufacturers setting up operations in the country. This has led to increased competition in the market, driving down prices and making vaccines more accessible to a wider range of customers.

Local special circumstances: One of the key factors driving growth in the Other Vaccines market in Central Asia is the region's susceptibility to infectious diseases. With a large population and a high incidence of infectious diseases such as hepatitis, there is a growing need for preventative measures such as vaccines.

Underlying macroeconomic factors: The Central Asian region has seen significant economic growth in recent years, which has led to an increase in healthcare spending. Governments in the region have also been investing heavily in healthcare infrastructure, further driving growth in the Other Vaccines market. Additionally, the ongoing COVID-19 pandemic has highlighted the importance of vaccines and preventative healthcare, leading to increased demand for vaccines in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.